Johann Pitout

Pathology and Laboratory Medicine, University of Calgary, Canada

Dr Johann Pitout is a Medical Microbiologist who completed his Medical Studies in South Africa in 1985 and qualified as a Medical Microbiologist by obtaining the FFPath (SA) degree from the College of Medicine of South Africa and M Med (Microbiol Path) from University of Stellenbosh in 1992. He then completed a postdoctoral fellowship at Dr Christine Sander’s laboratory in the Department of Medical Microbiology and Immunology, Creighton University, Omaha, Nebraska, USA. He returned to South Africa in 1996 to take a position of Consultant Microbiologist at the University of Free State and in 1999 became the Head of Medical Microbiology. He moved to the United Arab Emirates during 2000 to initiate a Diagnostic Microbiology service in Abu Dhabi. During 2001 he was offered a position as a Medical Microbiologist at Calgary Laboratory Service and Associate Professor at the University of Calgary.

His main research interests are resistance to antimicrobial agents among Gram-negative bacteria especially the characterization and molecular epidemiology of Newer beta-lactamases such as AmpC, Extended-spectrum beta-lactamases and Carbapenem Hydrolyzing enzymes. He has also been involved in population-based surveillance of studies investigating infections caused by organisms producing these newer types of b-lactamases. A more recent interest is the molecular characterization of mobile elements involved in the spread and maintenance of resistance genes among Gram-negative bacteria. He has published several papers in this field.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Infectious Diseases > Antimicrobials & Drug Resistance (since 24 November 2006)

All recent recommendations

• 3.0
  Is plasmid-mediated quinolone resistance a clinically significant problem?
  Recommended by Johann Pitout
  
• 3.0
  Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae.
  Recommended by Johann Pitout
  
• 3.0
  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
  Recommended by Johann Pitout
  
• 3.0
  Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.
  Recommended by Johann Pitout
  
• 3.0
  Long-term evolution of a nosocomial outbreak of Pseudomonas aeruginosa producing VIM-2 metallo-enzyme.
  Recommended by Johann Pitout
  
• 3.0
  The continuing challenge of ESBLs.
  Recommended by Johann Pitout
  
• 3.2
  Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
  Recommended by Raul Raz, Johann Pitout
  
• 3.0
  Are laboratory-based antibiograms reliable to guide the selection of empirical antimicrobial treatment in patients with hospital-acquired infections?
  Recommended by Johann Pitout
  
• 3.0
  Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.
  Recommended by Johann Pitout
  
• 6.0
  Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
  Recommended by Johann Pitout
  
• 3.0
  Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme.
  Recommended by Johann Pitout